Spinal Muscular Atrophy — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for spinal muscular atrophy. 13 active patents protecting 1 drugs from 1+ originators. First major cliff: 2033. Daily refresh.

1
Approved drugs
13
Active US patents
53/100
Avg vulnerability
$2.3B
Annual revenue covered

Originators in Spinal Muscular Atrophy

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Roche 13 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating spinal muscular atrophy. Each bar = one year. Y-axis scaled to peak year (4 patents).

2
33
2
35
3
36
4
38
2
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Evrysdi
RISDIPLAM
 Roche 13 53 $2.3B 2033-02-08

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9969754 Evrysdi method of use 75 2035-05-11
11827646 Evrysdi method of use 75 2036-01-25
12350273 Evrysdi method of use 75 2038-10-01
12350273 Evrysdi method of use 75 2038-10-01
11534444 Evrysdi method of use 75 2038-10-04
11827646 Evrysdi method of use 70 2036-01-25
11534444 Evrysdi method of use 70 2038-10-04
9969754 Evrysdi method of use 62 2035-05-11
11938136 Evrysdi formulation 55 2036-11-08
9586955 Evrysdi composition of matter 17 2033-02-08

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9586955 Evrysdi composition of matter 4 2033-02-08
12122789 Evrysdi composition of matter 17 2041-04-15
12122789 Evrysdi composition of matter 17 2041-04-15
9586955 Evrysdi composition of matter 17 2033-02-08
11938136 Evrysdi formulation 55 2036-11-08
9969754 Evrysdi method of use 62 2035-05-11
11534444 Evrysdi method of use 70 2038-10-04
11827646 Evrysdi method of use 70 2036-01-25
11534444 Evrysdi method of use 75 2038-10-04
12350273 Evrysdi method of use 75 2038-10-01

Related